Evidence map›Paper›PMID 27671229›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2017

Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.

Thomas C F Bodewes, Joel M Johnson, Michael Auster, Cindy Huynh, Sriya Muralidharan, Mauricio Contreras, Frank W LoGerfo, Leena Pradhan-Nabzdyk

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Thomas C F BodewesDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Joel M JohnsonDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Michael AusterDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Cindy HuynhDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Sriya MuralidharanDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Mauricio ContrerasDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Frank W LoGerfoDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Leena Pradhan-NabzdykDivision of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; lpradhan@bidmc.harvard.edu.
Harvard University · USBeth Israel Deaconess Medical Center · USUtrecht University · NL

Funding

HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
MECHANISMS OF PROSTHETIC ARTERIAL GRAFT FAILURER01HL021796 · NHLBI · NEW ENGLAND DEACONESS HOSPITAL · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1987 to 2020
$9.0M
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular SurgeryR01HL086741 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BHASIN, MANOJ, FERRAN, CHRISTIANE · 2007 to 2022
$7.4M
Harvard-Longwood Short-Term Research Training in Vascular SurgeryT35HL110843 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHRISTIANE FERRAN, FRANK W LOGERFO · 2013 to 2026
$609k
Development of Small Molecule Inhibitors of IL-18 to Prevent Intimal HyperplasiaR21HL133821 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PRADHAN-NABZDYK, LEENA, SUN, LIJUN · 2016 to 2017
$476k
NHLBI NIH HHS R01 HL021796NHLBI NIH HHS R01 HL086741NHLBI NIH HHS R21 HL133821NHLBI NIH HHS T32 HL007734NHLBI NIH HHS T35 HL110843
6 · The paper itself

Abstract

In an effort to inhibit the response to vascular injury that leads to intimal hyperplasia, this study investigated the in vivo efficacy of intraluminal delivery of thrombospondin-2 (TSP-2) small interfering RNA (siRNA). Common carotid artery (CCA) balloon angioplasty injury was performed in rats. Immediately after denudation, CCA was transfected intraluminally (15 min) with one of the following: polyethylenimine (PEI)+TSP-2 siRNA, saline, PEI only, or PEI+control siRNA. CCA was analyzed at 24 h or 21 d by using quantitative real-time PCR and immunohistochemistry. TSP-2 gene and protein expression were significantly up-regulated after endothelial denudation at 24 h and 21 d compared with contralateral untreated, nondenuded CCA. Treatment with PEI+TSP-2 siRNA significantly suppressed TSP-2 gene expression (3.1-fold) at 24 h and TSP-2 protein expression, cell proliferation, and collagen deposition up to 21 d. These changes could be attributed to changes in TGF-β and matrix metalloproteinase-9, the downstream effectors of TSP-2. TSP-2 knockdown induced anti-inflammatory M2 macrophage polarization at 21 d; however, it did not significantly affect intima/media ratios. In summary, these data demonstrate effective siRNA transfection of the injured arterial wall and provide a clinically effective and translationally applicable therapeutic strategy that involves nonviral siRNA delivery to ameliorate the response to vascular injury.-Bodewes, T. C. F., Johnson, J. M., Auster, M., Huynh, C., Muralidharan, S., Contreras, M., LoGerfo, F. W., Pradhan-Nabzdyk, L. Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.

Indexed as

Angioplasty, BalloonAnimalsCarotid Artery InjuriesCell ProliferationCollagenGene Expression RegulationMacrophagesMatrix Metalloproteinase 9RatsRNA, Small InterferingThrombospondin 2ThrombospondinsTransforming Growth Factor betaCollagenMatrix Metalloproteinase 9RNA, Small InterferingThrombospondin 2ThrombospondinsTransforming Growth Factor betaarterial injuryextracellular matrix proteinintimal hyperplasiasiRNAvascular remodeling

Identifiers

PMID27671229
PMCPMC5161524
OpenAlexW2526920853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.